web statistics
PRESS ROOM        PUBLICATIONS       CAREERS
AboutOur TechnologyCore AreasInvestor Relations & NewsPartneringContact
KineMed  ► Core Areas > Neuro

Understanding the Causal Mechanisms of Neurological Disorders

KineMed’s neuroscience program focuses on nervous system diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, cognitive disorders, and Amyotrophic Lateral Sclerosis, commonly called ALS and Lou Gehrig’s disease.

Key Capabilities

In neurodegeneration and central nervous systems (CNS) disorders, our biomarkers have applications in Parkinson’s Disease (PD), Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s Disease, Alzheimer’s Disease (AD), Huntington’s Disease, and Progressive Supranuclear Palsy (PSP). They can show microtubule turnover and neuronal cargo transport rates and have the potential to show beneficial effects of a candidate compound on these disorders and diseases.

The Company’s technologies are able to determine a drug’s effect on:

  • Neurogenesis, the formation of new nerve cells in the brain 
  • Microtubule stability, the turnover rate of microtubules in neurons as part of a disease process

  • Neuronal transport, the rate of movement of substances up and down nerve processes, necessary for neuronal health and intercellular communication.  

  • Myelin synthesis and breakdown, the basis of normal white matter structure and function and the central pathologic process in demyelinating diseases like multiple sclerosis

  • Neuroinflammation, the cells and mediators of inflammatory events in the brain

  • Amyloid beta and amyloid precursor protein turnover, underlying the most characteristic pathologic feature of Alzheimer’s disease 

This proprietary capability is the basis of collaborations with pharmaceutical companies. A typical neuroscience collaboration involves the use of our technologies to identify and assess neurogenic and neuroprotective drug candidates for the treatment of Alzheimer’s disease, Lou Gehrig’s disease (ALS), Huntington’s disease, Parkinson’s disease, and memory and cognitive disorders.  Neurogenic and neuroprotective drug development using our technologies has been the subject of multiple peer-reviewed publications by our scientists. 

Measuring axonal transport

Examples of Our Work

An example of our work is slowing neurodegenerative disease progression. We have demonstrated a proprietary CSF translational marker of disrupted neuronal transport of protein cargo and therapeutic stabilization.

The Company has developed and validated methods that enable the evaluation of changes in microtubule (MT) dynamics and MT-mediated neuronal transport, also called axonal transport, by measurement of labeled biomarkers in human cerebrospinal fluid (“CSF”). This fluid circulates through the ventricles of the brain, the cavity of the spinal cord, and the subarachnoid space and has relevance in Alzheimer’s disease and Parkinson’s disease.

Novel CSF Markers

  • Clinical validation studies ongoing in Parkinson’s, Alzheimer’s and ALS

  • Validated in several models of neurodegeneration (ALS, AD, HD, PD)

  • Minimal invasiveness facilitates clinical application

  • Direct quantitative assessment of drug effect in both animals and humans

  • Rapid readout



5980 Horton Street | Suite 470 | Emeryville, CA 94608 | Tel.: USA [1] 510.655.6525 | Fax: [1] 510.655.6506 | TOLL-FREE: 855.KINEMED 

 Copyright © 2014 KineMed, Inc.  |  All Rights Reserved  |  Privacy  |  Terms & Conditions